BYRON MAY: Open Payments
NPI 1275252199 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,582 in 106 payments from 16 companies in 2025. Trend: 2023 $1,467 · 2024 $3,047 · 2025 $2,582
Food & beverage: $2,582
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 13 | $335 |
| Fresenius USA Marketing, Inc. | 13 | $323 |
| Mallinckrodt Hospital Products Inc. | 5 | $266 |
| Novartis Pharmaceuticals Corporation | 10 | $264 |
| Otsuka America Pharmaceutical, Inc. | 8 | $233 |
| Ardelyx, Inc. | 12 | $228 |
| ANI Pharmaceuticals, Inc. | 7 | $179 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $156 |
| Travere Therapeutics, Inc. | 7 | $135 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $113 |
Products named: TARPEYO, VELPHORO, IBSRELA, Fabhalta, PURIFIED CORTROPHIN GEL, JYNARQUE, Kerendia, ACTHAR.
Industry payments across DE — which companies pay providers there.
